Table 1.
Baseline characteristics of 30 patients
| Characteristics | All patients (n = 30) |
|---|---|
| Age, years | |
| Mean (range) | 56.5 (25–73) |
| Sex | |
| Male | 19 (63.3) |
| Female | 11 (36.7) |
| ECOG performance status | |
| 0 | 30 (100) |
| 1 | 0 (0) |
| TNM stage at baseline | |
| IIIA | 5 (16.7) |
| IIIB | 13 (43.3) |
| IV | 12 (40.0) |
| History of hepatolithiasis | |
| Yes | 1 (3.3) |
| No | 29 (96.7) |
| HBsAg | |
| Positive | 8 (26.7) |
| Negative | 22 (73.3) |
| HBcAb | |
| Positive | 24 (80.0) |
| Negative | 6 (20.0) |
| Prior systemic therapy | |
| Yes | 0 (0) |
| No | 30 (100) |
| PD-L1 expression (IHC ≥ 1%a) | |
| Positive | 14 (46.7) |
| Negative | 16 (53.3) |
| CA19-9 (U/mL) | |
| ≥37 | 21 (70.0) |
| <37 | 9 (30.0) |
| DDR-related gene mutation | |
| Present | 21 (70.0) |
| Absent | 9 (30.0) |
| MSI status | |
| High | 2 (6.7) |
| Low | 3 (10.0) |
| Stable | 25 (83.3) |
| BRAF mutation | |
| Yes | 3 (10.0) |
| No | 27 (90.0) |
| FGFR2 fusions/arrangement | |
| Yes | 1 (3.3) |
| No | 29 (96.7) |
| IDH1 mutation | |
| Yes | 1 (3.3) |
| No | 29 (96.7) |
| Tumor mutation burden (Muts/Mb) | |
| Median (range) | 0.985 (0.08–31.82) |
ECOG Eastern Cooperative Oncology Group, HBsAg hepatitis B surface antigen, HBcAb hepatitis B core antibody, PD-L1 programmed cell death-ligand 1, CA19-9 carbohydrate antigen 19-9, DDR DNA damage response, MSI microsatellite instability, FGFR2 fibroblast growth factor receptor 2, IDH1 isocitrate dehydrogenase
aTumor area positivity (TAP) ≥ 1% was defined as positive. Proportion of tumor and/or immune cells with PD-L1 staining at any intensity